You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Patent: 8,354,234


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,354,234
Title:Mass spectrometric analysis of ligand conjugated magnetic nanoparticles
Abstract: The present invention provides methods, compositions, and systems for mass spectrometric analysis of magnetic nanoparticles displaying ligands on their surface. For example, the present invention provides methods of screening a sample for the presence of at least one analyte using ligand conjugated magnetic nanoparticles, magnetic separation, and mass spectrometric analysis. The present invention also relates to MALDI matrix compositions comprising ligand conjugated magnetic nanoparticles.
Inventor(s): Chen; Yu-Ju (Lugang Township, Changhua County, TW), Lin; Po-Chiao (Pingtung, TW), Lin; Chun-Cheng (Fongyuan, TW), Chen; Shu-Hua (Taipei, TW), Chou; Po-Hung (Taipei County, TW), Liao; Hsin-Kai (Taipei, TW)
Assignee: Academia Sinica (Taipei, TW)
Application Number:11/487,823
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 8,354,234

Introduction

The United States patent system is a complex and evolving landscape, particularly when it comes to the eligibility and validity of patent claims. This analysis will delve into the specifics of United States Patent 8,354,234, examining its claims, the broader patent landscape, and the critical issues surrounding patent eligibility and validity.

Background on Patent-Eligible Subject Matter

To understand the context of any patent, it is crucial to grasp the concept of patent-eligible subject matter. Section 101 of the Patent Act (35 U.S.C. §101) outlines four categories of patentable inventions: processes, machines, manufactures, and compositions of matter. However, the Supreme Court has developed judicial exceptions to these categories, excluding laws of nature, natural phenomena, and abstract ideas from patentability unless they contain an inventive concept that transforms the nature of the claim[1].

The Alice/Mayo Test

The Supreme Court's decisions in Alice Corp. v. CLS Bank International and Mayo Collaborative Services v. Prometheus Laboratories, Inc. established a two-step test to determine patent eligibility. First, the claims must not be directed to an ineligible concept. If they are, the second step assesses whether the claims have an inventive concept that transforms the nature of the claim into a patent-eligible application of the ineligible concept[1][3].

United States Patent 8,354,234: An Overview

While the specific details of Patent 8,354,234 are not provided in the sources, we can analyze it within the framework of current patent law and practices.

Claim Construction and Eligibility

To determine the validity of the claims in Patent 8,354,234, one must apply the Alice/Mayo test. If the claims are directed to an abstract idea, law of nature, or natural phenomenon, they must contain additional elements that transform the claim into a patent-eligible invention. For example, simply implementing an abstract idea on a generic computer does not suffice; the claims must include elements that are not conventional, routine, or well understood[1][3].

Specification and Enablement

The patent specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. This is a critical requirement under 35 U.S.C. §112(a), ensuring that the public knowledge is enriched by the patent specification to a degree commensurate with the scope of the claims[4].

The Role of the Patent Trial and Appeal Board (PTAB)

The Patent Trial and Appeal Board, established by the Leahy-Smith America Invents Act (AIA) in 2011, plays a significant role in challenging the validity of patents. PTAB conducts inter partes review (IPR) and post-grant review (PGR), which are faster and less expensive than judicial proceedings. These processes allow anyone to challenge patents before the USPTO, potentially canceling claims that PTAB concludes should not have been issued[3].

Challenges and Criticisms

The PTAB has been both praised and criticized. While it aims to improve patent quality and reduce unwarranted litigation costs, critics argue that it has made it too easy to challenge patents, creating uncertainty in patent rights and potentially stifling innovation[3].

Stakeholder Views and Legislative Developments

Stakeholders have varying views on the current state of patent-eligible subject matter jurisprudence. Some argue that the Alice/Mayo framework has negatively affected investment in technology and innovation. In response, legislative efforts such as the Patent Eligibility Restoration Act of 2023 (PERA 2023) have been proposed to replace the Alice/Mayo framework with a more defined list of ineligible categories[1].

Impact on Innovation and Investment

The patent landscape significantly influences innovation and investment in technology. The increasing complexity and uncertainty around patent eligibility can deter investment in emerging fields like AI and biotechnology. For instance, the narrowing of patent-eligible subject matter by the Supreme Court has affected the ability to patent certain types of inventions, such as isolated human DNA segments[1].

Technology and Patent Applications

The rise in patent applications, facilitated by technological advancements, has made the patent landscape more complex. Automated systems, such as the Patent Claims Analysis System, are being developed to help manage the vast number of claims and prior art, ensuring that patent examiners and applicants can efficiently review and analyze patent claims[2].

Examples and Statistics

  • The number of patent applications has significantly increased, from approximately 100,000 per year in the 1960s and 1970s to over 326,000 in 2001. This trend is driven by technological innovation and facilitated by technologies like word processing and remote electronic database searching[2].
  • The average legal costs for litigating a patent case in federal court can exceed $1 million, making PTAB processes a more attractive option for challenging patent validity[3].

Key Considerations for Patent Applicants

When applying for a patent, applicants must ensure that their claims meet the statutory requirements, including subject matter eligibility, novelty, nonobviousness, and definiteness. Here are some key considerations:

Subject Matter Eligibility

Ensure that the claims are not directed to ineligible concepts unless they contain an inventive concept that transforms the nature of the claim[1][3].

Specification and Enablement

The specification must provide sufficient detail to enable those skilled in the art to make and use the invention without undue experimentation[4].

Claim Construction

Claims should be carefully constructed to avoid being too broad or too narrow. The scope of the claims must be commensurate with the enablement provided by the specification[4].

Conclusion

The patent landscape in the United States is complex and dynamic, with ongoing debates and legislative efforts aimed at clarifying and refining the standards for patent-eligible subject matter. For Patent 8,354,234, or any patent, understanding these nuances is crucial for navigating the patent system effectively.

Key Takeaways

  • Patent-Eligible Subject Matter: Section 101 of the Patent Act sets out the categories of patentable inventions, but judicial exceptions narrow these categories.
  • Alice/Mayo Test: A two-step test to determine if claims are directed to an ineligible concept and if they contain an inventive concept.
  • PTAB and IPR/PGR: Administrative challenges to patent validity that are faster and less expensive than judicial proceedings.
  • Legislative Developments: Efforts like PERA 2023 aim to clarify and refine patent-eligible subject matter.
  • Impact on Innovation: Uncertainty in patent eligibility can affect investment in emerging technologies.

FAQs

Q: What are the categories of patentable inventions under Section 101 of the Patent Act? A: The categories include any new and useful process, machine, manufacture, or composition of matter[1].

Q: What is the Alice/Mayo test, and how does it apply to patent claims? A: The Alice/Mayo test is a two-step process to determine if claims are directed to an ineligible concept and if they contain an inventive concept that transforms the nature of the claim[1][3].

Q: What is the role of the Patent Trial and Appeal Board (PTAB) in challenging patent validity? A: PTAB conducts inter partes review (IPR) and post-grant review (PGR) to challenge the validity of patents, providing a faster and less expensive alternative to judicial proceedings[3].

Q: How has the number of patent applications changed over the years, and what factors contribute to this trend? A: The number of patent applications has significantly increased, driven by technological innovation and facilitated by technologies like word processing and remote electronic database searching[2].

Q: What are the key considerations for ensuring that a patent specification meets the requirements under 35 U.S.C. §112(a)? A: The specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation, and the scope of the claims must be commensurate with the enablement provided by the specification[4].

Sources

  1. CRS Reports: Patent-Eligible Subject Matter Reform: An Overview[1].
  2. Google Patents: Patent Claims Analysis System and Method[2].
  3. CRS Reports: The Patent Trial and Appeal Board and Inter Partes Review[3].
  4. USPTO: 2161-Three Separate Requirements for Specification Under 35 U.S.C. §112(a)[4].

More… ↓

⤷  Subscribe

Details for Patent 8,354,234

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAPLAS pooled plasma (human), solvent/detergent treated For Injection 125416 January 17, 2013 ⤷  Subscribe 2025-07-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.